Brainstorm Cell Therapeutics (STU:GHD) Cyclically Adjusted FCF per Share: €-26.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:GHD Brainstorm Cell Therapeutics Inc STU:GHD
29 GF Score
Price €2.98
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Cyclically Adjusted FCF per Share?

Brainstorm Cell Therapeutics STU:GHD 29 Cyclically Adjusted FCF per Share is €-26.47 as of Mar. 2026. GuruFocus rates STU:GHD with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Brainstorm Cell Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.103. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-26.47 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 1.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -3.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Brainstorm Cell Therapeutics was 17.10% per year. The lowest was -15.90% per year. And the median was -0.25% per year.

As of today (2026-07-22), Brainstorm Cell Therapeutics's current stock price is €2.979. Brainstorm Cell Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-26.47. Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Brainstorm Cell Therapeutics  (STU:GHD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Brainstorm Cell Therapeutics Cyclically Adjusted FCF per Share Related Terms


Brainstorm Cell Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Brainstorm Cell Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brainstorm Cell Therapeutics Cyclically Adjusted FCF per Share Chart

Brainstorm Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.17 -7.66 -7.69 -11.94 -46.33

Brainstorm Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.35 -23.86 -36.88 -46.33 -26.47

STU:GHD vs ADAPY, APRE, JSPR: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Brainstorm Cell Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


STU:GHD
29GF Score
Brainstorm Cell Therapeutics Inc STU:GHD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brainstorm Cell Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Brainstorm Cell Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.103/330.2130*330.2130
=-0.103

Current CPI (Mar. 2026) = 330.2130.

Brainstorm Cell Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -1.048 241.018 -1.436
201609 -0.205 241.428 -0.280
201612 -0.916 241.432 -1.253
201703 -1.232 243.801 -1.669
201706 -1.184 244.955 -1.596
201709 2.518 246.819 3.369
201712 -2.010 246.524 -2.692
201803 -1.386 249.554 -1.834
201806 -0.105 251.989 -0.138
201809 -4.099 252.439 -5.362
201812 -2.437 251.233 -3.203
201903 -0.533 254.202 -0.692
201906 -2.159 256.143 -2.783
201909 -2.281 256.759 -2.934
201912 -2.151 256.974 -2.764
202003 -7.180 258.115 -9.186
202006 -2.598 257.797 -3.328
202009 -2.866 260.280 -3.636
202012 -2.892 260.474 -3.666
202103 -3.168 264.877 -3.949
202106 -1.836 271.696 -2.231
202109 -2.352 274.310 -2.831
202112 -2.027 278.802 -2.401
202203 -1.382 287.504 -1.587
202206 -2.394 296.311 -2.668
202209 -2.014 296.808 -2.241
202212 -1.798 296.797 -2.000
202303 -1.520 301.836 -1.663
202306 -2.364 305.109 -2.559
202309 -2.036 307.789 -2.184
202312 -0.877 306.746 -0.944
202403 -0.653 312.332 -0.690
202406 -0.329 314.175 -0.346
202409 -0.560 315.301 -0.586
202412 -0.175 315.605 -0.183
202503 -0.238 319.799 -0.246
202506 -0.352 322.561 -0.360
202509 -0.085 324.800 -0.086
202512 -0.057 324.054 -0.058
202603 -0.103 330.213 -0.103

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-26.47 mean?
Brainstorm Cell Therapeutics (STU:GHD) has a Cyclically Adjusted FCF per Share of €-26.47 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Brainstorm Cell Therapeutics and its competitors.
Is Brainstorm Cell Therapeutics' Cyclically Adjusted FCF per Share too high?
Brainstorm Cell Therapeutics' current Cyclically Adjusted FCF per Share is €-26.47. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Cyclically Adjusted FCF per Share compare to ADAPY and APRE?
Brainstorm Cell Therapeutics' Cyclically Adjusted FCF per Share of €-26.47 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Brainstorm Cell Therapeutics and its competitors. Brainstorm Cell Therapeutics's current Cyclically Adjusted FCF per Share is €-26.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (STU:GHD) has a current Cyclically Adjusted FCF per Share of €-26.47. The current Cyclically Adjusted FCF per Share is €-26.47. Brainstorm Cell Therapeutics' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (STU:GHD), the current Cyclically Adjusted FCF per Share is €-26.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Other Exchanges BCLI:USA
Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
29GF Score

Get the complete analysis for STU:GHD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.98
Price